| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Profit before tax | -2.0 | -1.8 |
| Net income | -2.3 | -1.7 |
| EPS (diluted, $ a share) | $-0.42 | $-0.44 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: MTRI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
InMed Pharmaceuticals Inc.: key numbers
- Share price
- $17.50Close, Nov 17
- Market cap
- $96.1M
- Shares outstanding
- 5.49MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from InMed Pharmaceuticals Inc.
All →InMed Pharmaceuticals M&A Deal with Mentari Therapeutics, Inc.
InMed Pharmaceuticals Inc. (now renamed Mentari Therapeutics, Inc.) completed its previously announced business combination with private Delaware corporation Mentari Therapeutics on November 6, 2026. This filing provides the required historical financial statements and management's discussion for the acquired Mentari entity for the period ended September 30, 2026. The combined company now trades on Nasdaq under the ticker 'MTRI'.
- Counterparty
- Mentari Therapeutics, Inc.
InMed Pharmaceuticals Signs $490M M&A Deal with Mentari Therapeutics, Inc.
InMed Pharmaceuticals Inc. (renamed Mentari Therapeutics, Inc.) completed its business combination with private Delaware corporation Mentari Therapeutics, Inc. on November 6, 2026. The transaction included a pre-closing financing that raised $490 million in aggregate gross proceeds. The combined company will focus on developing therapies for migraine prevention and is led by the Mentari management team.
- Value
- $490M
- Counterparty
- Mentari Therapeutics, Inc.
InMed Pharmaceuticals Insider ADAR1 Capital Management LLC Buys $34.6K of Stock
ADAR1 Capital Management LLC bought 2,640 shares of InMed Pharmaceuticals Inc. at $13.10 a share, worth $34.6K in total on Nov 5, 2026. Shares held after the trade: 98,297 (+2.8%).
- Value
- $34.6K
- Shares
- 2,640
- Price
- $13.10
- Holding change
- +2.8%
- Trade date
- Nov 5, 2026
InMed Pharmaceuticals Signs $490M M&A Deal with InMed Pharmaceuticals Inc.
Mentari Therapeutics completed its merger with InMed Pharmaceuticals Inc. and began trading on Nasdaq under the ticker 'MTRI'. In connection with the closing, the company completed $490 million in private placement financings to fund its pipeline of migraine prevention biologics, including MT-001 and MT-002.
- Value
- $490M
- Counterparty
- InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Reverse Stock Split
InMed Pharmaceuticals completed a 1-for-10 reverse stock split (consolidation), reducing its outstanding shares from approximately 5.49 million to 549,374. The company also legally changed its name to Mentari Therapeutics, Inc. and confirmed shareholder approval of all matters at its 2026 Annual General and Special Meeting.
InMed Pharmaceuticals Reverse Stock Split
InMed Pharmaceuticals Inc. (renamed Mentari Therapeutics, Inc.) completed a 1-for-10 reverse stock split (consolidation) of its common shares effective November 4, 2026. The split reduced the outstanding share count from approximately 5.49 million to 0.55 million shares to facilitate its pending merger and reorganization with Mentari Therapeutics, Inc. (Delaware).